寨卡病毒治疗的小分子药物与抗体
综述寨卡病毒药物研发现状。已发现的小分子抑制剂和治疗性抗体中,部分在小鼠模型中显示有前景的疗效;多数抑制剂通过筛选美国食品药品监督管理局批准药物和临床试验化合物获得,但均不够强效以支持开展寨卡临床试验。因孕妇是寨卡治疗主要目标人群,候选药物可经两阶段路径开发:先在非孕妇中证明安全有效,再快速推进至孕妇中评估安全性和有效性。
要点
- 已发现的小分子抑制剂和治疗性抗体中,部分在小鼠模型中显示有前景的疗效。
- 多数抑制剂通过筛选美国食品药品监督管理局批准药物和临床试验化合物获得,但均不够强效以支持开展寨卡临床试验。
- 候选药物可经两阶段路径开发:先在非孕妇中证明安全有效,再快速推进至孕妇中评估安全性和有效性。
核心结论
- 已发现的小分子抑制剂和治疗性抗体中,部分在小鼠模型中显示有前景的疗效,但均不够强效以支持开展寨卡临床试验。
- 因孕妇是寨卡治疗主要目标人群,候选药物可经两阶段路径开发:先在非孕妇中证明安全有效,再快速推进至孕妇中评估安全性和有效性。
研究设计与样本
- 本文为综述,回顾寨卡病毒药物研发的当前状态。
主要发现
- 已发现的小分子抑制剂和治疗性抗体中,部分在小鼠模型中显示有前景的疗效。
- 多数抑制剂通过筛选美国食品药品监督管理局批准药物和临床试验化合物获得,但均不够强效以支持开展寨卡临床试验。
- 登革治疗也采用了药物重定位策略,几种化合物在临床试验中测试但未显示临床获益。
临床怎么用
- 作者提出候选药物可经两阶段路径开发:第一阶段应在非孕妇患者中证明安全性和有效性;一旦在非孕妇患者中证明有效性,候选药物应快速推进至第二阶段,在孕妇患者中评估安全性和有效性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zika virus (ZIKV) infection during pregnancy can cause devastating congenital abnormities or fetal demise. Zika virus infection could also cause Guillain-Barré syndrome in adults. Mosquito control, vaccine, and therapeutics are 3 potential, effective means to prevent ZIKV infection. Here we review the current status of ZIKV drug discovery. Both small molecule inhibitors and therapeutic antibodies have been identified, some of which have shown promising efficacy in mouse models. Most inhibitors were identified through screening US Food and Drug Administration-approved drugs and clinical trial compounds; however, none of them were potent enough to justify a ZIKV clinical trial. Such a repurposing approach has also been pursued for dengue therapy, with several compounds tested in clinical trials showing no clinical benefits. Because pregnant women are the main target population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path. The first stage should demonstrate safety and efficacy in nonpregnant patients. Once efficacy has been demonstrated in nonpregnant patients, the candidates should be rapidly advanced to stage 2 for safety and efficacy evaluation in pregnant patients. The 2-stage developmental path is supported by previous results from trials with other viral infections that showed that treatment of pregnant women with antiviral drugs or hyperimmunoglobulins significantly reduced congenital abnormalities in neonates.
引用
- Xie X, Zou J, Shan C, et al. Small Molecules and Antibodies for Zika Therapy. J Infect Dis. 2017. PMID: 29267911. doi:10.1093/infdis/jix406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。